| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥5224.1B | ¥4922.7B | +6.1% |
| Operating Income | ¥144.5B | ¥151.2B | -4.4% |
| Ordinary Income | ¥154.6B | ¥165.4B | -6.5% |
| Net Income | ¥93.5B | ¥106.4B | -12.1% |
| ROE | 6.3% | 7.1% | - |
FY2026 Q3 cumulative results: Revenue 522.4B yen (YoY +6.1%), Operating Income 14.5B yen (YoY -4.4%), Ordinary Income 15.5B yen (YoY -6.5%), Net Income 9.4B yen (YoY -12.1%). Revenue increased driven by Medical Supply business expansion with new SPD contracts and multi-hospital agreements, while profit declined due to rising labor costs, material procurement price increases amid yen depreciation, and absence of prior-year large senior condominium sales in Total Pack Produce business. Gross profit margin remained at 8.8%, constrained by cost pressures. Progress toward full-year guidance (Revenue 700.0B yen, Operating Income 26.0B yen, Net Income 15.5B yen) stands at 74.6% for revenue, 55.6% for operating income, and 60.5% for net income as of Q3, indicating need for second-half profit margin improvement to meet targets.
Revenue increased 30.1B yen (+6.1%) driven primarily by Medical Supply business growth (+7.5%) through new SPD contract commencements (3 facilities, approx. 950 beds) starting April and July, and successful launch of multi-hospital consolidated contracts with different management entities. Medical Supply segment expanded to 274 facilities nationwide covering approximately 101,000 beds. Total Pack Produce business grew 3.0% as large project cases progressed on schedule and medical IT solution demand remained robust.
Operating income declined 0.7B yen (-4.4%) as gross profit margin remained at 8.8%, pressured by procurement price inflation due to yen depreciation and constrained pricing pass-through capacity. Selling, general and administrative expenses increased in absolute terms with rising minimum wage impacts on labor and dispatch costs, and utility cost increases particularly affecting Life Care operations. The profit decline also reflects absence of prior-year large senior condominium completion and sales in Total Pack Produce segment.
Ordinary income decreased 1.1B yen (-6.5%), with the gap from operating income explained by decline in equity method investment income from affiliates. Net income fell 1.3B yen (-12.1%), with effective tax rate at 39.0% (tax burden coefficient 0.612) compressing post-tax profitability. Treasury stock decreased significantly from negative 15.5B yen to negative 5.0B yen (+10.5B yen reduction in negative balance), likely due to treasury stock disposal associated with multiple corporate reorganizations including 5-company consolidation in Medical Supply (October 2024), 2-company consolidation in Life Care (January 2025), and 4-company consolidation in Dispensing Pharmacy (April 2025), though specific capital policy details were not disclosed.
Non-recurring factors: Absence of prior-year large senior condominium project in Total Pack Produce segment represents non-recurring revenue/profit variance. LED delivery delays causing project completion postponements and radiology equipment procurement price spikes due to yen depreciation represent operational headwinds but not extraordinary accounting items.
Performance pattern: Revenue up/Profit down, driven by top-line expansion offset by margin compression from cost inflation and operational leverage constraints.
Medical Supply business (72.5% of total revenue) is the core segment, generating revenue of 378.4B yen (+7.5% YoY) and operating income of 4.8B yen (+13.1% YoY) with operating margin of 1.3%. This segment drove overall revenue growth through new SPD contract wins (3 facilities, 950 beds operational from H1) expanding nationwide footprint to 274 facilities and 101,000 beds, and successful launch of multi-hospital consolidated contracts. The 5-company consolidation completed October 2024 enhanced purchasing power and hospital pricing negotiation capability. Operating profit growth outpaced revenue growth, demonstrating improving operational leverage and efficiency from consolidation benefits. As a trading-intensive model, the 1.3% margin is structurally thin but improving trajectory is positive.
Total Pack Produce business contributed revenue of 91.4B yen (+3.0%) and operating income of 5.0B yen (-24.3%) with margin of 5.5%. Revenue growth reflects planned progression of large project cases (weighted toward second half) and strong medical information systems solution demand. Operating profit declined substantially due to absence of prior-year large senior condominium completion/sales, LED delivery delays postponing renovation project completions, and radiology equipment procurement price inflation from yen depreciation. Excluding the non-recurring condominium factor, underlying project business performance aligns with management guidance.
Dispensing Pharmacy business generated revenue of 25.8B yen (+2.8%) and operating income of 3.1B yen (+20.9%) with margin of 11.9%, the highest among all segments. The 4-company consolidation completed April 2025 realized significant synergies including recruitment cost reduction and operational efficiency gains, improving operating margin from 10.1% to 11.9%. Store count decreased from 130 to 129 as management closed 5 unprofitable stores while adding 4 new locations. This disciplined portfolio optimization and integration-driven margin expansion demonstrates effective execution.
Life Care business recorded revenue of 28.2B yen (+1.9%) and operating income of 1.7B yen (-2.3%) with margin of 6.1%. The 2-company consolidation completed January 2025 and overhead cost review initiated September aim to improve efficiency. However, utility cost increases, occupancy rate decline from prior year, food material cost inflation, and labor shortage-driven dispatch/outsourcing cost increases pressured profitability. While occupancy rates remain high in absolute terms, year-over-year deterioration and uncontrolled cost inflation present ongoing margin challenges.
Segment profit contribution: Medical Supply drove revenue growth but Total Pack Produce's 24.3% profit decline significantly impacted consolidated operating income. Dispensing Pharmacy's strong margin improvement partially offset pressures but insufficient to overcome total profit headwinds given its smaller scale.
Profitability: ROE 6.3% (DuPont components: Net Profit Margin 1.8%, Asset Turnover 1.343x, Financial Leverage 2.61x), Operating Margin 2.8%, EBIT Margin 2.8%. ROE of 6.3% is structurally modest, driven by thin net profit margin characteristic of trading-intensive business model. Asset turnover of 1.343x exceeds industry median of 1.06x, indicating relatively efficient asset utilization. Operating margin of 2.8% is below industry median of 3.2%, reflecting cost pressure and lower-margin business mix impacts.
Efficiency: Days Sales Outstanding (DSO) 94 days, significantly longer than industry median of 73.57 days, indicating room for improvement in receivables collection management. Days Inventory Outstanding 51 days approximates industry median range. Days Payables Outstanding reflected in electronically recorded obligations of 43.5B yen. Extended DSO represents working capital pressure and potential cash conversion cycle concern.
Financial Health: Equity Ratio 38.4%, below industry median of 47.8%, indicating higher financial leverage relative to peers. Current Ratio 134.8%, below industry median of 188%, but Quick Ratio 120.4% remains adequate for near-term liquidity. Current liabilities of 200.2B yen dominate total liabilities, requiring monitoring of short-term debt maturity profile, though cash deposits of 78.5B yen provide substantial buffer (cash/current liabilities ratio approximately 39.2%).
Leverage: Total interest-bearing debt 27.6B yen (short-term borrowings 0.8B yen, long-term debt 26.8B yen), Debt-to-Capital Ratio 15.6%, Net Debt effectively negative given cash holdings substantially exceed debt. Debt structure is well-balanced and financial risk remains low.
Operating Cash Flow: Not disclosed in available financial data, preventing direct assessment of cash earnings quality and calculation of OCF/Net Income ratio. The absence of operating cash flow disclosure limits evaluation of profit-to-cash conversion efficiency.
Investing Cash Flow: Not disclosed. Capital expenditure details not provided, though qualitative disclosures indicate significant investment in SHIP Grand Base Tokyo logistics hub (floor area 4,274 tsubo, approximately 14,100 sqm) with automated warehouse RENATUS system, and IT infrastructure investments for medical DX initiatives. Scale of capex relative to depreciation cannot be quantified.
Financing Cash Flow: Not disclosed. Dividend payment of 58 yen per share at period-end is confirmed. Treasury stock decreased by 10.5B yen (negative balance reduction), likely reflecting stock disposals associated with corporate reorganizations rather than share buybacks.
Free Cash Flow: Cannot be calculated due to lack of operating CF and capex data.
Cash generation: Cannot be definitively assessed without cash flow statement data. However, cash and deposits of 78.5B yen remain substantial (vs. 77.5B yen in prior period), suggesting adequate liquidity maintenance despite profit decline. The short-term debt coverage (cash/short-term debt approximately 102.8x) indicates strong near-term payment capacity, but lack of operating CF disclosure prevents assessment of sustainable cash generation capability and dividend coverage quality.
Ordinary Income vs. Net Income: Ordinary income of 15.5B yen exceeded operating income of 14.5B yen by 1.0B yen, attributable to net non-operating income of 1.0B yen (non-operating income 1.6B yen including dividend income, interest income, and foreign exchange gains, less non-operating expenses 0.6B yen). The gap between ordinary income (15.5B yen) and net income (9.4B yen) of 6.1B yen primarily reflects tax burden, with income before tax of 15.3B yen and effective tax rate of 39.0%. No material extraordinary gains or losses disclosed, indicating earnings derived from ordinary business operations.
Accruals and Cash Quality: Operating CF data unavailable prevents calculation of accruals ratio (Net Income - Operating CF). Extended DSO of 94 days raises concerns about receivables quality and timing of cash realization. Accounts receivable of 134.6B yen represents 25.8% of revenue, elevated relative to cash conversion timing. Without operating CF disclosure, earnings quality assessment based on profit-to-cash conversion remains incomplete. This represents a material information gap for earnings quality evaluation.
Recurring vs. Non-recurring: Absence of prior-year large senior condominium sales in Total Pack Produce segment constitutes a non-recurring variance (approximately 2.4B yen operating income impact given segment's 24.3% profit decline). Underlying recurring business performance shows Medical Supply and Dispensing Pharmacy executing well on integration strategies, while Life Care faces persistent cost inflation headwinds.
Overall Quality Assessment: Earnings quality warrants monitoring due to (1) thin margins vulnerable to cost fluctuations, (2) extended receivables collection period, and (3) lack of operating cash flow transparency. While no accounting irregularities are evident, structural profitability challenges and working capital management issues require attention.
Full-year guidance: Revenue 700.0B yen (+3.2% YoY), Operating Income 26.0B yen (+4.9% YoY), Ordinary Income 26.5B yen (+1.8% YoY), Net Income 15.5B yen (+2.5% YoY), Annual dividend 60 yen per share.
Q3 progress rate: Revenue 74.6%, Operating Income 55.6%, Ordinary Income 58.3%, Net Income 60.5%. Against standard quarterly progression (Q3=75%), revenue tracking on pace, but operating income significantly trails at 55.6%, indicating need for substantial second-half profit acceleration. Operating income must reach 11.5B yen in Q4 alone (vs. Q3 YTD average of 4.8B yen per quarter) to achieve full-year target.
Progress assessment: Revenue guidance appears achievable given 74.6% attainment and business momentum. Operating income guidance requires 79.5% improvement in Q4 vs. Q3 run rate, representing aggressive second-half weighting. Management commentary indicates large project cases in Total Pack Produce are weighted toward second half as planned, and consolidation synergies continue to materialize. However, cost inflation pressures (labor, procurement, utilities) persist and pricing pass-through execution remains critical variable.
Key drivers for guidance achievement: (1) Total Pack Produce segment large project completions and revenue recognition in Q4, (2) sustained consolidation synergies in Medical Supply and Dispensing Pharmacy, (3) successful pricing pass-through to offset cost inflation, (4) receivables collection improvement to reduce DSO, and (5) operational leverage from SHIP Grand Base Tokyo full-scale operations commencing February 2026.
Guidance unchanged from initial plan, indicating management confidence despite H1 profit shortfall. Risk factors include further yen depreciation impacting procurement costs, LED or equipment delivery delays, and labor cost acceleration.
Dividend: Period-end dividend of 58 yen per share declared, with full-year guidance of 60 yen per share (interim dividend not specified in available data). Based on net income of 9.4B yen for Q3 cumulative and period-end dividend of 58 yen, calculated payout ratio approximately 58.3%. This approaches upper bound of sustainable payout range, particularly given profit decline of 12.1% YoY.
Dividend sustainability: Full-year net income guidance of 15.5B yen and annual dividend of 60 yen per share implies guidance-based payout ratio of approximately 60% (based on share count implied by EPS guidance of 166.85 yen). Payout ratio elevated relative to typical sustainable range of 30-50%, though cash deposits of 78.5B yen provide near-term payment capacity. Without operating cash flow disclosure, assessment of dividend coverage by cash generation remains incomplete. If profit deteriorates below guidance, dividend sustainability may face pressure given already-elevated payout ratio.
Share buybacks: Not disclosed in available materials. Treasury stock decreased by 10.5B yen (negative balance reduced from 15.5B yen to 5.0B yen), but this reflects disposal associated with corporate reorganizations (stock exchanges for M&A consolidations) rather than market buyback activity. Total return ratio cannot be calculated without buyback data.
Shareholder return policy: Dividend policy details not explicitly disclosed beyond full-year 60 yen guidance. Elevated payout ratio warrants clarification of sustainable policy parameters and management's capital allocation priorities between growth investment, balance sheet strength, and shareholder returns.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 6.3% vs. Industry Median 3.7% (2025-Q3, IQR: 2.2%-8.4%, n=15). Company's ROE exceeds industry median, ranking in upper half of trading sector peer group. However, absolute ROE level remains modest at 6.3%, constrained by thin net profit margin of 1.8% vs. industry median of 2.0%. Operating Margin 2.8% vs. Industry Median 3.2% (IQR: 1.3%-4.6%), positioning below median and indicating room for margin improvement relative to peers.
Efficiency: Asset Turnover 1.343x vs. Industry Median 1.06x (IQR: 0.70-1.32), demonstrating superior asset utilization efficiency ranking in upper quartile. Days Sales Outstanding (DSO) 94 days vs. Industry Median 73.57 days (IQR: 64.79-91.11), indicating receivables collection notably slower than typical peer, warranting collection management enhancement.
Financial Health: Equity Ratio 38.4% vs. Industry Median 47.8% (IQR: 43.0%-55.5%), positioning below median with higher financial leverage. Current Ratio 1.35x vs. Industry Median 1.88x (IQR: 1.64x-2.38x), below peer median but adequate given substantial cash holdings. Net Debt/EBITDA effectively negative (cash exceeds debt) vs. Industry Median -2.14 (IQR: -6.31 to -0.01), indicating strong debt serviceability comparable to net cash peer group.
Growth: Revenue Growth 6.1% vs. Industry Median 2.6% (IQR: -5.3%-10.8%), ranking in upper quartile and demonstrating strong top-line momentum relative to trading sector. Net Profit Growth -12.1% (proxy via EPS Growth YoY median 0.31, IQR: -0.06-1.97) positions below median, reflecting margin pressure challenges despite revenue outperformance.
Industry Context: Trading sector (n=15 companies) with comparison to FY2025-Q3 period peer medians. Company demonstrates superior revenue growth and asset efficiency but faces profitability and working capital management challenges relative to peers. Source: Proprietary analysis of publicly available trading sector earnings data.
Margin compression risk from persistent cost inflation: Gross profit margin of 8.8% faces ongoing pressure from (a) procurement price increases due to yen depreciation particularly for radiology equipment, (b) minimum wage increases driving labor and dispatch costs across all segments, and (c) utility and food material cost inflation in Life Care operations. Limited pricing pass-through capacity in competitive medical supply distribution market constrains ability to recover cost increases. Quantified impact: Operating income declined 4.4% despite 6.1% revenue growth, indicating approximately 1,000 basis point negative operating leverage. Without successful pricing negotiations or further consolidation synergies, sustained margin pressure threatens profitability trajectory.
Working capital deterioration and cash conversion risk: DSO of 94 days significantly exceeds industry median of 73.57 days and represents approximately 20 days excess or 14.5B yen incremental working capital tied up (based on daily revenue of 7.2B yen). Extended collection period increases credit risk exposure, constrains cash generation, and reduces financial flexibility. Combined with lack of operating cash flow disclosure, visibility into cash earnings quality remains limited. Deteriorating receivables aging or collection issues could materially impact liquidity despite current strong cash position.
Guidance achievement risk requiring aggressive second-half profit acceleration: Q3 operating income progress of 55.6% vs. 75% standard requires 11.5B yen Q4 operating income (2.4x Q3 quarterly average of 4.8B yen) to meet full-year 26.0B yen target. Achievement depends on (a) timely completion and revenue recognition of back-end weighted Total Pack Produce projects, (b) no further LED or equipment delivery delays, (c) realization of planned consolidation synergies, and (d) containment of cost inflation. Missing guidance could pressure stock valuation and raise concerns about earnings visibility, particularly given elevated 60% dividend payout ratio limiting buffer for profit shortfalls.
Key Takeaways from Earnings - Significant Characteristics and Trends:
Strategic business model transformation progressing through consolidation-driven scale benefits: The completion of three major consolidations (Medical Supply 5 companies October 2024, Life Care 2 companies January 2025, Dispensing Pharmacy 4 companies April 2025) demonstrates management commitment to operational leverage and margin improvement. Dispensing Pharmacy integration results are quantitatively evident, with operating margin expanding from 10.1% to 11.9% (+180bps) and operating income growing 20.9% despite modest 2.8% revenue growth. Medical Supply segment achieving 13.1% operating income growth on 7.5% revenue growth indicates successful realization of purchasing power and negotiation capability enhancements. This consolidation strategy combined with infrastructure investments (SHIP Grand Base Tokyo) positions company to capture multi-hospital consolidated SPD contracts representing structural market share opportunity. The 10.5B yen reduction in treasury stock negative balance (from 15.5B yen to 5.0B yen) associated with these transactions indicates material capital deployment to strategic M&A integration.
Revenue growth momentum strong but profitability conversion challenged by structural margin pressures requiring operational response: 6.1% revenue growth significantly outpaces industry median of 2.6%, driven by Medical Supply new contract wins expanding to 274 facilities and 101,000 beds nationwide, and medical IT solution demand strength. However, operating income declined 4.4% with operating margin of 2.8% below industry median of 3.2%, reflecting structural challenges in translating top-line growth to bottom-line results. The 8.8% gross margin and extended 94-day DSO (vs. 73.57-day industry median) indicate business model characteristics requiring active management. Full-year guidance achievement demanding 2.4x Q4 profit acceleration suggests management confidence in project timing and integration benefits, but execution risk remains elevated. The thin margin profile typical of trading operations leaves limited buffer for cost volatility or operational missteps.
Long-term positioning enhanced by medical DX infrastructure demand and BCP value proposition, though near-term earnings quality monitoring essential: Strategic initiatives including medical DX capabilities, RFID tracking system development with Nippon Express, hospital renovation network through MF Green Association, and dual-hub BCP infrastructure align with secular healthcare facility modernization trends and resilience requirements. The February 2026 SHIP Grand Base Tokyo launch with 75% picking time reduction through automation demonstrates technology-enabled efficiency gains supporting future margin expansion potential. However, near-term financial transparency gaps (no operating cash flow disclosure) and earnings quality concerns (low cash conversion suggested by extended DSO, elevated payout ratio of 60% limiting financial flexibility) warrant careful monitoring. Sustained evaluation should track quarterly DSO trends, consolidation synergy realization pace, and second-half guidance achievement as key indicators of strategy execution and financial health trajectory.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
Financial results briefing materials for SHIP HEALTHCARE HOLDINGS, INC. (Securities Code 3360) for the third quarter of the fiscal year ending March 2026. Net sales increased by +6.1% to 5,224 hundred million yen, achieving top-line growth, while operating income declined by -4.4% to 14,400 million yen, ordinary income decreased by -6.5% to 15,400 million yen, and net income fell by -10.8% to 9,300 million yen. In the TPP business, profits declined this fiscal year due to the absence of the large senior condominium completion recorded in the prior year. The MSP business commenced operations at three newly contracted SPD facilities (approx. 950 beds) from the first half, and operational efficiencies progressed through the integration of five companies effective October 1, 2024. The LC business was affected by rising utilities and labor costs, while the PH business generated integration synergies following the completion of the integration of four companies effective April 1, 2025. At the group level, progress is generally in line with the initial plan, and on the profit side, the integration of the PH business is delivering quantifiable improvement effects. Full-year guidance calls for net sales of 7,000 hundred million yen, operating income of 26,000 million yen, ordinary income of 26,500 million yen, net income of 15,500 million yen, and a dividend of 60 yen.
In the TPP business, large-scale project initiatives are progressing largely as planned under a second-half-weighted schedule, and the healthcare IT solutions business is performing well; however, profits declined due to a reactionary drop following the prior year’s completion and sale of a large senior condominium project. In the MSP business, three newly contracted SPD facilities (approx. 950 beds) commenced operations from April and July, and a bundled SPD contract covering multiple hospitals with different parent organizations has started. In the PH business, the completion of the integration of four companies has realized integration synergies such as reductions in recruitment development costs, improving the operating margin from 10.1% to 11.9%. The Greater Tokyo medical materials logistics hub “SHIP Granbase Tokyo” began operations in February 2026, establishing a framework centered on the RENATUS automated warehouse system with a total floor area of 4,274 tsubo and approximately 70,800 items handled. ODA-specialized trading company Tech International Co., Ltd. (50 projects annually) joined the Group as of May 27, 2025, strengthening business development in the overseas healthcare domain.
Full-year plan forecasts net sales of 7,000 hundred million yen (+3.2% YoY), operating income of 26,000 million yen, ordinary income of 26,500 million yen, and net income of 15,500 million yen. In the TPP business, large-scale projects are second-half-weighted with 7,115 million yen planned in 4Q. In the MSP business, 116,024 million yen is planned in the second half (4Q), targeting segment sales of 494,500 million yen driven by the full-year contribution of new SPD facilities and full-scale operations at SHIP Granbase Tokyo. The LC business plans 8,841 million yen in the second half (second-half plan), and the PH business anticipates 8,616 million yen in the second half (4Q plan).
Management stated that “at the group level, progress is generally in line with the initial plan,” and “on the profit side, the integration of the PH business is delivering quantifiable improvement effects.” In the second half, the company aims to recover the full-year operating margin to 3.7% through full-scale recognition of large TPP projects, contributions from new facilities in the MSP business, and full operation of SHIP Granbase Tokyo. The dividend plan is 60 yen for the full year, including a 58 yen year-end dividend, with a policy to maintain a payout ratio of approximately 58% (based on full-year net income of 15,500 million yen).
With the commencement of operations in February 2026 at the Greater Tokyo medical materials logistics hub “SHIP Granbase Tokyo,” establish an advanced logistics platform centered on the Japan-origin automated warehouse system RENATUS, leveraging AI, robotics, and RFID. Develop a joint tracking system with Nippon Express utilizing RFID to track and manage the location of medical materials in real time from shipment to delivery. Demonstrate comprehensive capabilities centered on the MSP business through intra-group reorganization and integration: completed the integration of five MSP companies effective October 1, 2024; two LC companies effective January 1, 2025; and four PH companies effective April 1, 2025, thereby enhancing creditworthiness and negotiating power, strengthening inventory management and logistics capabilities, and accumulating analytical know-how (IT adoption, SIP, digital twin). Strengthen the system for handling renovation projects: Green Hospital Supply launched the association of construction partner firms “MF Green Association” in 2024 (28 companies at present) to enhance responsiveness to the increasing number of renovation works (e.g., operating theaters, ICU equipment works, and partial refurbishments of medical facilities). Expand the IT solutions business: Establishment of the Medical DX Promotion Department has boosted demand for network infrastructure development projects, enabling end-to-end provision of network/security design and construction, healthcare information systems and network consulting, virtual platform design and construction, and security consulting.
Rising procurement prices and increases in personnel/dispatch costs due to higher minimum wages (MSP business). Yen depreciation driving higher procurement costs for radiotherapy equipment (TPP business). Higher utility expenses and a decline in occupancy rate versus the prior year despite maintaining a high occupancy level (LC business). Rising food material costs and surging dispatch and outsourcing fees due to labor shortages (LC and FD businesses). Recognition of one-off expenses such as M&A fees in 1Q (TPP business).